Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AMGEN INC Director's Dealing 2024

Mar 8, 2024

29819_dirs_2024-03-08_19273122-968e-4d77-85f1-b923ccde063b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2024-03-06

Reporting Person: Khosla Rachna (SVP, Business Development)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-03-06 Common Stock A 1256 Acquired 8597 Direct

Footnotes

F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 102 RSUs which will vest on 5/5/2024; 252 RSUs which will vest in installments of 124 on 4/30/2024 and 128 on 4/30/2025; 784 RSUs which will vest in installments of 386 on 11/5/2024 and 398 on 11/5/2025; 606 RSUs which will vest in installments of 199 on 5/2/2024, 200 on 5/2/2025, and 207 on 5/2/2026; and 593 RSUs which will vest in in installments of 195 on 5/2/2025, 196 on 5/2/2026 and 202 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2: These shares include 148 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.